Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Primary Cervical Cancer Screening by Self-sampling HPV Test

NCT05613283 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05613283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05613283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Primary Cervical Cancer Screening by Self-sampling HPV Test
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
November 19, 2022
Completion date
August 31, 2027
Enrollment
17,875 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma in situ, atypical glandular cells, atypical glandular cells not otherwise specified, atypical glandular cells, favor neoplastic, atypical squamous cells of undetermined significance, atypical squamous cells, cannot rule out high-grade squamous intraepithelial lesion, cervical adenocarcinoma, cervical cancer, cervical intraepithelial neoplasia grade i, cervical intraepithelial neoplasia grade ii, cervical intraepithelial neoplasia, grade iii, cervical squamous cell carcinoma, cervical squamous intraepithelial lesion, high-grade squamous intraepithelial lesions, human papillomavirus infection, low-grade squamous intraepithelial lesions, negative for intraepithelial lesion or malignancy